CN117460511A - 含有二氢哒嗪-3,5-二酮衍生物的制剂 - Google Patents
含有二氢哒嗪-3,5-二酮衍生物的制剂 Download PDFInfo
- Publication number
- CN117460511A CN117460511A CN202280041019.3A CN202280041019A CN117460511A CN 117460511 A CN117460511 A CN 117460511A CN 202280041019 A CN202280041019 A CN 202280041019A CN 117460511 A CN117460511 A CN 117460511A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- weight
- less
- formula
- compound represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-096206 | 2021-06-08 | ||
| JP2021096206 | 2021-06-08 | ||
| PCT/JP2022/023076 WO2022260064A1 (ja) | 2021-06-08 | 2022-06-08 | ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117460511A true CN117460511A (zh) | 2024-01-26 |
Family
ID=84426023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280041019.3A Pending CN117460511A (zh) | 2021-06-08 | 2022-06-08 | 含有二氢哒嗪-3,5-二酮衍生物的制剂 |
Country Status (12)
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105073715A (zh) * | 2013-03-13 | 2015-11-18 | 中外制药株式会社 | 二氢哒嗪-3,5-二酮衍生物 |
| WO2016039458A1 (ja) * | 2014-09-12 | 2016-03-17 | 中外製薬株式会社 | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 |
| CN112533608A (zh) * | 2018-09-03 | 2021-03-19 | 正大天晴药业集团股份有限公司 | 包含 1,3,5-三嗪衍生物或其盐的固体药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012012421A (es) | 2010-04-28 | 2012-12-17 | Astellas Pharma Inc | Compuestos tetrahidrobenzotiofena. |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| PL2772490T3 (pl) | 2011-10-27 | 2016-11-30 | Aminoalkilo-podstawiona pochodna n-tienylobenzamidu | |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| US9499553B2 (en) * | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
| SMT202100481T1 (it) | 2014-08-18 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni per profarmaci di aripiprazolo |
| MX376202B (es) | 2016-08-15 | 2025-03-07 | Lilly Co Eli | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. |
| WO2019060604A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE MEDICINE |
-
2022
- 2022-06-08 WO PCT/JP2022/023076 patent/WO2022260064A1/ja not_active Ceased
- 2022-06-08 KR KR1020237045200A patent/KR20240018523A/ko active Pending
- 2022-06-08 US US18/567,435 patent/US20240293402A1/en active Pending
- 2022-06-08 AU AU2022288895A patent/AU2022288895A1/en active Pending
- 2022-06-08 CA CA3221186A patent/CA3221186A1/en active Pending
- 2022-06-08 IL IL309056A patent/IL309056A/en unknown
- 2022-06-08 EP EP22820243.8A patent/EP4353233A4/en active Pending
- 2022-06-08 MX MX2023014507A patent/MX2023014507A/es unknown
- 2022-06-08 CN CN202280041019.3A patent/CN117460511A/zh active Pending
- 2022-06-08 TW TW111121208A patent/TW202317118A/zh unknown
- 2022-06-08 JP JP2023527886A patent/JPWO2022260064A1/ja active Pending
- 2022-06-08 BR BR112023023708A patent/BR112023023708A2/pt unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105073715A (zh) * | 2013-03-13 | 2015-11-18 | 中外制药株式会社 | 二氢哒嗪-3,5-二酮衍生物 |
| WO2016039458A1 (ja) * | 2014-09-12 | 2016-03-17 | 中外製薬株式会社 | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 |
| CN112533608A (zh) * | 2018-09-03 | 2021-03-19 | 正大天晴药业集团股份有限公司 | 包含 1,3,5-三嗪衍生物或其盐的固体药物组合物 |
Non-Patent Citations (2)
| Title |
|---|
| GALLANT, KMH ET AL.: "EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients", KIDNEY INTERNATIONAL, vol. 99, no. 5, 24 May 2021 (2021-05-24), pages 1225 - 1233 * |
| TSUBOI, Y ET AL.: "EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder", KIDNEY INTERNATIONAL, vol. 98, no. 2, 12 August 2020 (2020-08-12), pages 343 - 354 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240018523A (ko) | 2024-02-13 |
| MX2023014507A (es) | 2024-01-26 |
| EP4353233A1 (en) | 2024-04-17 |
| BR112023023708A2 (pt) | 2024-01-30 |
| AU2022288895A1 (en) | 2024-01-18 |
| US20240293402A1 (en) | 2024-09-05 |
| IL309056A (en) | 2024-02-01 |
| TW202317118A (zh) | 2023-05-01 |
| WO2022260064A1 (ja) | 2022-12-15 |
| JPWO2022260064A1 (cg-RX-API-DMAC7.html) | 2022-12-15 |
| EP4353233A4 (en) | 2025-06-25 |
| CA3221186A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7627302B2 (ja) | パルボシクリブの固形剤形 | |
| TWI325318B (en) | Capsule and method of manufacturing the same | |
| BG64691B1 (bg) | Зипрасидонови препарати | |
| TW201531309A (zh) | N-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕苯甲醯胺之藥學組成物 | |
| KR101352130B1 (ko) | 디클로페낙 제제 및 이용 방법 | |
| CA2919522A1 (en) | Formulation of syk inhibitors | |
| TW202317136A (zh) | 穩定之伐尼克蘭劑型 | |
| EP3525792A1 (en) | Powder for oral suspension containing lamotrigine | |
| US10583087B2 (en) | Pharmaceutical composition for oral administration | |
| JP2022524424A (ja) | 向上したバイオアベイラビリティを有する化合物形態及びその製剤 | |
| JP2008044960A (ja) | 経口固形医薬 | |
| WO2021216545A1 (en) | Oral solid meloxicam formulations for the treatment of acute pain | |
| WO2022260064A1 (ja) | ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤 | |
| HK40104119A (en) | Formulation containing dihydropyridazine-3,5-dione derivative | |
| Thompson et al. | Can the oral bioavailability of the discontinued prostate cancer drug galeterone Be improved by processing method? KinetiSol® outperforms spray drying in a head-to-head comparison | |
| JP7109255B2 (ja) | 粉砕物の製造方法及び錠剤の製造方法 | |
| EP3162368A1 (en) | Pharmaceutical composition for oral administration | |
| JP7820568B2 (ja) | 溶出性及び打錠性に優れた製剤 | |
| Munnangi | Advancing Pharmaceutical Manufacturing: Innovative Applications of Hot Melt Extrusion for the Preparation of Drug Complexes and Fixed Dose Combination Immediate Release Formulation with Diverse Crystalline Properties | |
| EP4059504A1 (en) | Drug substance of lemborexant and medicinal composition comprising same | |
| EP4721739A1 (en) | Csf-1r inhibitor pharmaceutical composition, preparation method therefor and pharmaceutical use thereof | |
| TW202448468A (zh) | 一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用 | |
| TW202333702A (zh) | 具有優異溶出性之醫藥組成物 | |
| HK40051811A (en) | Diclofenac formulations and methods of use | |
| CA3166050A1 (en) | Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40104119 Country of ref document: HK |